<DOC>
	<DOCNO>NCT00683735</DOCNO>
	<brief_summary>Objective : To assess effect co-administration sitagliptin metformin compare placebo incretin effect ( base comparison insulin secretory response oral glucose load 'isoglycaemic ' intravenous glucose load ) . Hypothesis : Treatment co-administration sitagliptin metformin provide great incretin effect compare placebo .</brief_summary>
	<brief_title>Quantification Dipeptidyl Peptidase ( DPP ) -4 Inhibition-mediated Enhancement Activity Entero-insular Axis</brief_title>
	<detailed_description>A new class antidiabetic agent , DPP-4 inhibitor , think protect endogenously secrete incretin hormone ( e.g. , GLP-1 GIP ) proteolytic degradation inactivation . Since GLP-1 antidiabetogenic property , augmentation meal-related response intact , biologically active GLP-1 expect increase impact incretin stimulation insulin secretory response . The incretin effect type 2 diabetic patient reduce due impaired secretion GLP-1 reduce insulinotropic effectiveness GIP . Therefore , sitagliptin ( DPP-4 inhibitor ) study 20 type 2-diabetic patient , treat sequentially ( crossover design ) ( ) placebo , ( b ) metformin alone , ( c ) Sitagliptin alone , ( ) combination metformin Sitagliptin period 6 day ( washout period 3 day treatment . The insulin secretory response ( insulin , C-peptide , insulin secretion rate determine deconvolution analysis ) compare experiment oral glucose ( 75 g ) `` isoglycaemic '' intravenous glucose infusion ( 20 % glucose i.v. ) . The difference represent `` incretin effect '' . It expect incretin effect type 2-diabetic patient enhance sitagliptin treatment , especially combine metformin . A secondary objective relate potential increase % incretin contribution insulin secretory response oral glucose ( incretin effect ) change oral glucose-induced response intact GLP-1 GIP ( measure specific RIAs ) . Thus , establish , degree sitagliptin act `` incretin enhancer '' type 2 diabetic patient . This study also determine combination sitagliptin metformin affect incretin response insulin secretory response . Metformin standard widely use antihyperglycemic agent lower glycemic level primarily suppression hepatic glucose output improvement peripheral insulin resistance , result increase glucose transport utilization skeletal muscle . There data suggest metformin increase endogenous GLP-1 level response oral glucose load obese human ( 1 ) . Therefore relevance confirm novel activity metformin patient type 2 diabetes , assess potential functional consequence regard incretin effect .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Type 2diabetes mellitus BMI 2535 kg/m2 HbA1c 6.5 % 9 % ( without OHA medication ) HbA1c 6 % 8.5 % ( OHA monotherapy metformin sulfonylurea ) Patient understand studyprocedures Type 1diabetes mellitus Cpeptide &lt; 0.7ng/mL ( 0.23 nmol/L ) Patient take oral antihyperglycemic agent ( OHA ) within prior 12 week , except metformin sulfonylurea Patient require insulin therapy within past 12 week</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Incretin , DPP-4 , metformin , sitagliptin , insulin secretion</keyword>
</DOC>